Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance

Diffuse Large B-Cell Lymphoma: Current Strategies and Future Directions

(2017) Jennifer L. Cultrera et al.   Cancer Control

Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer

(2014) Ekta Agarwal et al.   BMC CANCER

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

(2014) Yuichi Ando et al.   CANCER SCIENCE

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

(2014) Jason R. Westin   Clinical Lymphoma Myeloma & Leukemia

Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis

(2014) Alberto Ocana et al.   PLoS One

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies

(2014) Sarah K. Tasian et al.   Frontiers in Oncology

Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab

(2013) Zi-Zhen Xu et al.   ANNALS OF HEMATOLOGY

PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma

(2013) Matthias Pfeifer et al.   CELL CYCLE

Two Birds with One Stone: Dual p110δ and p110γ Inhibition

(2013) Klaus Okkenhaug   CHEMISTRY & BIOLOGY

Novel therapeutic targets in diffuse large B-cell lymphoma

(2013) Georg Lenz   EJC SUPPLEMENTS

p87 and p101 Subunits Are Distinct Regulators Determining Class IBPhosphoinositide 3-Kinase (PI3K) Specificity

(2013) Aliaksei Shymanets et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial andin vitrostudies

(2013) Daphne R. Friedman et al.   LEUKEMIA & LYMPHOMA

Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma

(2013) Chuanbing Zang et al.   LEUKEMIA & LYMPHOMA

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

(2013) Ningshu Liu et al.   MOLECULAR CANCER THERAPEUTICS

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

(2013) M. Pfeifer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy

(2012) Daniel C. Cho et al.   CANCER

mTOR inhibitors in cancer therapy

(2012) Yekaterina Y. Zaytseva et al.   CANCER LETTERS

Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma

(2012) A. M. Petrich et al.   CLINICAL CANCER RESEARCH

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

(2012) D. Mahadevan et al.   EUROPEAN JOURNAL OF CANCER

Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: A clinicopathological study

(2012) Neerja Vajpayee et al.   LEUKEMIA RESEARCH

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

(2011) E. Campo et al.   BLOOD

CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies

(2011) Jorge J Castillo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium

(2010) Sonali M. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

(2010) T E Witzig et al.   LEUKEMIA

Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies

(2010) Bertrand Coiffier et al.   LEUKEMIA & LYMPHOMA

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Class I PI3K in oncogenic cellular transformation

(2008) L Zhao et al.   ONCOGENE